Skip to main content
. 2024 Aug 2;13(5):1415–1430. doi: 10.1007/s40120-024-00644-3

Fig. 3.

Fig. 3

Patient shares of classes of products available for MS. Figure includes real-world data (2020–2022) as well as projections (2023–2028)